Cargando…

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow

Next Generation Flow (NGF) represents a gold standard for the evaluation of Minimal Residual Disease (MRD) in Multiple Myeloma (MM) patients at any stage of treatment. Although the assessment of MRD is still not universally employed in clinical practice, numerous studies have demonstrated the streng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pacelli, Paola, Raspadori, Donatella, Bestoso, Elena, Gozzetti, Alessandro, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742464/ https://www.ncbi.nlm.nih.gov/pubmed/36518304 http://dx.doi.org/10.3389/fonc.2022.1057713

Ejemplares similares

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
por: Zhou, Liang
Publicado: (2022)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Anesthesia and Oncology: Friend or Foe?
por: Buddeberg, Bigna S., et al.
Publicado: (2022)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Malignancy and IFITM3: Friend or Foe?
por: Rajapaksa, Ushani S., et al.
Publicado: (2020)

Editorial: Anesthesia and cancer: Friend or foe?
por: Bezu, Lucillia, et al.
Publicado: (2022)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Immune System, Friend or Foe of Oncolytic Virotherapy?
por: Filley, Anna C., et al.
Publicado: (2017)

Oral microbiota in oropharyngeal cancers: Friend or foe?
por: Nocini, Riccardo, et al.
Publicado: (2022)

ARID1A in cancer: Friend or foe?
por: Fontana, Beatrice, et al.
Publicado: (2023)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
por: Kim, Sung‐Min, et al.
Publicado: (2020)

The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
por: Lopes, Raquel, et al.
Publicado: (2021)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Anesthesia and Cancer, Friend or Foe? A Narrative Review
por: Montejano, Julio, et al.
Publicado: (2021)

The Role of SETBP1 in Gastric Cancer: Friend or Foe
por: Fang, Fujin, et al.
Publicado: (2022)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)
por: Abruzzese, Elisabetta, et al.
Publicado: (2023)

Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
por: van Schaik, Thijs A., et al.
Publicado: (2021)

The RNA-Binding Motif Protein Family in Cancer: Friend or Foe?
por: Li, Zhigang, et al.
Publicado: (2021)

Influence of gut microbiome on multiple myeloma: friend or foe?
por: Ahmed, Nausheen, et al.
Publicado: (2020)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
por: Ippoliti, Micaela, et al.
Publicado: (2012)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6kilh74ge48nq45hsnj7gcvi1v